| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Cancer Therapy: Preclinical |
Departments of 1 Surgical Oncology and 2 Cancer Biology, University of Texas M.D. Anderson Cancer Center, Houston, Texas
Requests for reprints: Lee M. Ellis, Department of Surgical Oncology, Box 444, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030-4009. Phone: 713-792-6926; Fax: 713-792-4689; E-mail:lellis{at}mdanderson.org.
Targeted therapies that inhibit the activity of tyrosine kinase receptors such as the epidermal growth factor receptor (EGFR) have shown activity against solid malignancies when used as single agents or in combination with chemotherapy. Although anti-EGFR therapies are active in some patients, eventually disease in nearly all patients will become refractory to therapy. Therefore, a better understanding of the mechanisms of resistance to anti-EGFR therapies is critical to further improve the efficacy of this class of agents. Mechanisms that mediate resistance to anti-EGFR therapies include the presence of redundant tyrosine kinase receptors, increased angiogenesis, and the constitutive activation of downstream mediators. Two recent landmark publications have also shown that specific mutations in the kinase domain of EGFR in some lung carcinomas are associated with markedly improved response rates to an EGFR tyrosine kinase inhibitor. Mutations in the EGFR receptor seem to play a significant role in determining the sensitivity of tumor cells to EGFR inhibitor therapy by altering the conformation and activity of the receptor. As the field of molecular therapeutics continues to evolve, a comprehensive understanding of resistance mechanisms will ultimately lead to refinements in our regimens to provide better care for patients with cancer.
Key Words: Epidermal growth factor receptor • resistance • tyrosine kinase receptor • signaling
This article has been cited by other articles:
|
|
 |
|
  F. Ciardiello and G. Tortora EGFR Antagonists in Cancer Treatment N. Engl. J. Med., March 13, 2008; 358(11): 1160 - 1174. [Full Text] [PDF]
|
|
|
|
 |
|
 P. C. Black, G. A. Brown, T. Inamoto, M. Shrader, A. Arora, A. O. Siefker-Radtke, L. Adam, D. Theodorescu, X. Wu, M. F. Munsell, et al. Sensitivity to Epidermal Growth Factor Receptor Inhibitor Requires E-Cadherin Expression in Urothelial Carcinoma Cells Clin. Cancer Res., March 1, 2008; 14(5): 1478 - 1486. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Cavazzoni, R. R. Alfieri, C. Carmi, V. Zuliani, M. Galetti, C. Fumarola, R. Frazzi, M. Bonelli, F. Bordi, A. Lodola, et al. Dual mechanisms of action of the 5-benzylidene-hydantoin UPR1024 on lung cancer cell lines Mol. Cancer Ther., February 1, 2008; 7(2): 361 - 370. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Ferrari and P. Foa Targeted Therapies: Cui Prodest? J. Clin. Oncol., October 10, 2007; 25(29): 4691 - 4692. [Full Text] [PDF]
|
|
|
|
|
|
H. Huynh, P. K.H. Chow, and K.-C. Soo AZD6244 and doxorubicin induce growth suppression and apoptosis in mouse models of hepatocellular carcinoma Mol. Cancer Ther., September 1, 2007; 6(9): 2468 - 2476. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. M. Hoff and L. M. Ellis Targeted Therapy Trials: Approval Strategies, Target Validation, or Helping Patients? J. Clin. Oncol., May 1, 2007; 25(13): 1639 - 1641. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Tabernero The Role of VEGF and EGFR Inhibition: Implications for Combining Anti-VEGF and Anti-EGFR Agents Mol. Cancer Res., March 1, 2007; 5(3): 203 - 220. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. V. Sequist Second-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer Oncologist, March 1, 2007; 12(3): 325 - 330. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Wang, S. Zhang, G. T. MacLennan, J. N. Eble, A. Lopez-Beltran, X. J. Yang, C.-X. Pan, H. Zhou, R. Montironi, and L. Cheng Epidermal Growth Factor Receptor Protein Expression and Gene Amplification in Small Cell Carcinoma of the Urinary Bladder Clin. Cancer Res., February 1, 2007; 13(3): 953 - 957. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. R Hutcheson, J. M Knowlden, H. E Jones, R. S Burmi, R. A McClelland, D. Barrow, J. M W Gee, and R. I Nicholson Inductive mechanisms limiting response to anti-epidermal growth factor receptor therapy Endocr. Relat. Cancer, December 1, 2006; 13(Supplement_1): S89 - S97. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Jin, K. K. Iwata, A. Belldegrun, R. Figlin, A. Pantuck, Z.-F. Zhang, R. Lieberman, and J. Rao Effect of an epidermal growth factor receptor tyrosine kinase inhibitor on actin remodeling in an in vitro bladder cancer carcinogenesis model. Mol. Cancer Ther., July 1, 2006; 5(7): 1754 - 1763. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Van Schaeybroeck, J. Kyula, D. M. Kelly, A. Karaiskou-McCaul, S. A. Stokesberry, E. Van Cutsem, D. B. Longley, and P. G. Johnston Chemotherapy-induced epidermal growth factor receptor activation determines response to combined gefitinib/chemotherapy treatment in non-small cell lung cancer cells Mol. Cancer Ther., May 1, 2006; 5(5): 1154 - 1165. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Reardon, J. A. Quinn, J. J. Vredenburgh, S. Gururangan, A. H. Friedman, A. Desjardins, S. Sathornsumetee, J. E. Herndon II, J. M. Dowell, R. E. McLendon, et al. Phase 1 Trial of Gefitinib Plus Sirolimus in Adults with Recurrent Malignant Glioma Clin. Cancer Res., February 1, 2006; 12(3): 860 - 868. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. X. Yang, R. M. Simon, A. R. Tan, D. Nguyen, and S. M. Swain Gene Expression Patterns and Profile Changes Pre- and Post-Erlotinib Treatment in Patients with Metastatic Breast Cancer Clin. Cancer Res., September 1, 2005; 11(17): 6226 - 6232. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
